Phathom Pharmaceuticals, Inc.
PHAT
$3.31
$0.165.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.86% | 81.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.86% | 81.41% | |||
| Cost of Revenue | -2.39% | 61.93% | |||
| Gross Profit | -4.08% | 84.69% | |||
| SG&A Expenses | 23.20% | 0.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.54% | 2.22% | |||
| Operating Income | -32.73% | 16.07% | |||
| Income Before Tax | -26.68% | 13.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.68% | 13.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.68% | 13.00% | |||
| EBIT | -32.73% | 16.07% | |||
| EBITDA | -32.86% | 16.12% | |||
| EPS Basic | -25.06% | 20.87% | |||
| Normalized Basic EPS | -25.05% | 20.86% | |||
| EPS Diluted | -25.06% | 20.87% | |||
| Normalized Diluted EPS | -25.05% | 20.86% | |||
| Average Basic Shares Outstanding | 1.30% | 9.93% | |||
| Average Diluted Shares Outstanding | 1.30% | 9.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||